Showing results (11-20 of 253) with videos related to

Sort By:
Pageof 26
Expert Review of Hematology|April 12, 2017
Post-transplant cyclophosphamide, a promising anti-graft versus host disease prophylaxis: where do we stand?Alberto Mussetti, Raffaella Greco, Jacopo Peccatori, et al.
European Journal of Haematology|January 4, 2013
Long-term molecular remission with lenalidomide treatment of relapsed chronic lymphocytic leukemiaFrancesco Spina, Francesca Rezzonico, Lucia Farina, et al.
Leukemia & Lymphoma|November 4, 2014
Recurrent Hodgkin lymphoma: toward a new definition of candidates for autologous stem cell transplant in the era of positron emission tomography scan and novel agentsAntonello Pinto, Paolo Corradini, Alberto Mussetti, et al.
European Journal of Haematology|May 7, 2014
Current status of haematopoietic autologous stem cell transplantation in lymphoid malignancies: a European perspectiveKai Hübel, Javier de la Rubia, Nabih Azar, et al.
The Journal of Molecular Diagnostics : JMD|August 31, 2018
Noninvasive Molecular Monitoring in Multiple Myeloma Patients Using Cell-Free Tumor DNA: A Pilot StudyGiulia Biancon, Silvia Gimondi, Antonio Vendramin, et al.
Bone Marrow Transplantation|December 12, 2018
Real-life feasibility of salvage allogeneic transplantation in peripheral T-cell lymphomasAlberto Mussetti, Nicolò Martinetti, Nicoletta Cieri, et al.
Hemasphere|January 17, 2020
Are We Ready to Treat Diffuse Large B-cell and High-Grade Lymphoma According to Major Genetic Subtypes?Annalisa Chiappella, Jennifer Crombie, Anna Guidetti, et al.
International Journal of Molecular Sciences|April 12, 2022
Targeting the DNA Damage Response to Increase Anthracycline-Based Chemotherapy Cytotoxicity in T-Cell LymphomaMartina Magni, Chiara Paolizzi, Chiara Monfrini, et al.
Leukemia Research|April 17, 2026
An Italian Delphi consensus on the current and future burden and clinical management of lenalidomide-refractory multiple myelomaPaolo Corradini, Pellegrino Musto, Carlotta Galeone, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 24, 2014
Graft monocytic myeloid-derived suppressor cell content predicts the risk of acute graft-versus-host disease after allogeneic transplantation of granulocyte colony-stimulating factor-mobilized peripheral blood stem cellsAntonio Vendramin, Silvia Gimondi, Anisa Bermema, et al.
Pageof 26